|
1) Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005; 23: 479-90
|
|
|
|
2) Roussel L, Erard M, Cayrol C, et al. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 2008; 9: 1006-12
|
|
|
|
|
|
3) Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007; 179: 2551-5
|
|
|
|
|
|
4) Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008; 223: 20-38
|
|
|
|
|
|
5) Pushparaj PN, Tay HK, H'Ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A. 2009; 106: 9773-8
|
|
|
|
|
|
6) Funakoshi-Tago M, Tago K, Hayakawa M, et al. Traf6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal. 2008; 20: 1679-86
|
|
|
|
|
|
7) Drube S, Heink S, Walter S, et al. The receptor tyrosine kinase c-kit controls IL-33 receptor signaling in mast cells. Blood. 115(19): 3899-906
|
|
|
|
|
|
8) Iwahana H, Yanagisawa K, Ito-Kosaka A, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem. 1999; 264: 397-406
|
|
|
|
|
|
9) Hayakawa H, Hayakawa M, Kume A, et al. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007; 282: 26369-80
|
|
|
|
|
|
10) Bulek K, Swaidani S, Qin J, et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol. 2009; 182: 2601-9
|
|
|
|
|
|
11) Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: An IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 2009; 30: 439-46
|
|
|
|
|
|
12) Luthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009; 31: 84-98
|
|
|
|
|
|
13) Ali S, Nguyen DQ, Falk W, et al. Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem Biophys Res Commun. 2009; 391: 1512-6
|
|
|
|
|
|
14) Hoshino K, Kashiwamura S, Kuribayashi K, et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med. 1999; 190: 1541-8
|
|
|
|
|
|
15) Townsend MJ, Fallon PG, Matthews DJ, et al. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000; 191: 1069-76
|
|
|
|
|
|
16) Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008; 20: 791-800
|
|
|
|
|
17) Guo L, Wei G, Zhu J, et al. IL-1 family members and stat activators induce cytokine production by Th2, Th17, and th1 cells. Proc Natl Acad Sci U S A. 2009; 106: 13463-8
|
|
|
|
|
|
18) Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood. 2009; 113: 1526-1534
|
|
|
|
|
|
19) Smithgall MD, Comeau MR, Yoon BR, et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008; 20: 1019-30
|
|
|
|
|
|
20) Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5＋ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol. 2008; 181: 4780-90
|
|
|
|
|
|
21) Kropf P, Schopf LR, Chung CL, et al. Expression of Th2 cytokines and the stable Th2 marker ST2L in the absence of IL-4 during leishmania major infection. Eur J Immunol. 1999; 29: 3621-8
|
|
|
|
|
|
22) Ho LH, Ohno T, Oboki K, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FCεRI signals. J Leukoc Biol. 2007; 82: 1481-90
|
|
|
|
|
|
23) Moulin D, Donze O, Talabot-Ayer D, et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007; 40: 216-25
|
|
|
|
|
|
24) Iikura M, Suto H, Kajiwara N, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007; 87: 971-8
|
|
|
|
|
|
25) Allakhverdi Z, Smith DE, Comeau MR, et al. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 2007; 179: 2051-4
|
|
|
|
|
|
26) Perrigoue JG, Saenz SA, Siracusa MC, et al. MHC class II-dependent basophil-CD4＋ T cell interactions promote T(h)2 cytokine-dependent immunity. Nat Immunol. 2009; 10: 697-705
|
|
|
|
|
|
27) Sokol CL, Chu NQ, Yu S, et al. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat Immunol. 2009; 10: 713-20
|
|
|
|
|
|
28) Yoshimoto T, Yasuda K, Tanaka H, et al. Basophils contribute to T(h)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4＋ T cells. Nat Immunol. 2009; 10: 706-12
|
|
|
|
|
|
29) Suzukawa M, Iikura M, Koketsu R, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol. 2008; 181: 5981-9
|
|
|
|
|
|
30) Schneider E, Petit-Bertron AF, Bricard R, et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol. 2009; 183: 3591-7
|
|
|
|
|
|
31) Cherry WB, Yoon J, Bartemes KR, et al. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008; 121: 1484-90
|
|
|
|
|
|
32) Smith DE. IL-33: A tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy. 2010; 40: 200-8
|
|
|
|
|
|
33) Suzukawa M, Koketsu R, Iikura M, et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest. 2008; 88: 1245-53
|
|
|
|
|
|
34) Allakhverdi Z, Comeau MR, Smith DE, et al. CD34＋ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol. 2009; 123: 472-8
|
|
|
|
|
|
35) Moro K, Yamada T, Tanabe M, et al. Innate production of T(h)2 cytokines by adipose tissue-associated c-kit(＋)sca-1(＋) lymphoid cells. Nature. 2010; 463: 540-544
|
|
|
|
|
|
36) Kurowska-Stolarska M, Stolarski B, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol. 2009; 183: 6469-77
|
|
|
|
|
|
37) Kuroiwa K, Li H, Tago K, et al. Construction of elisa system to quantify human ST2 protein in sera of patients. Hybridoma. 2000; 19: 151-9
|
|
|
|
|
|
38) Oshikawa K, Yanagisawa K, Tominaga S, et al. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy. 2002; 32: 1520-6
|
|
|
|
|
|
39) Prefontaine D, Lajoie-Kadoch S, Foley S, et al. Increased expression of IL-33 in severe asthma: Evidence of expression by airway smooth muscle cells. J Immunol. 2009; 183: 5094-103
|
|
|
|
|
|
40) Gudbjartsson DF, Bjornsdottir US, Halapi E, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet. 2009; 41: 342-7
|
|
|
|
|
|
41) Reijmerink NE, Postma DS, Bruinenberg M, et al. Association of IL1RL1, IL18R1, and IL18RAP gene cluster polymorphisms with asthma and atopy. J Allergy Clin Immunol. 2008; 122: 651-4 e658
|
|
|
|
|
|
42) Mangan NE, Dasvarma A, McKenzie AN, et al. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol. 2007; 37: 1302-12
|
|
|
|
|
|
43) Kung TT, Stelts D, Zurcher JA, et al. Mast cells modulate allergic pulmonary eosinophilia in mice. Am J Respir Cell Mol Biol. 1995; 12: 404-409
|
|
|
|
|
|
44) Prefontaine D, Nadigel J, Chouiali F, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol. 2009; 125: 752-4
|
|
|
|
|